Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany

Abstract.Premature infants have an increased risk of developing complicated respiratory syncytial virus (RSV) infections. Epidemiological data on RSV-related hospitalizations are a prerequisite to develop guidelines for the use of preventive measures. The objective of this study was to determine incidence and risk factors of RSV-related rehospitalizations (RSV-RH) of premature infants. We recruited 1,103 infants with a gestational age of less than 35 weeks, primarily admitted to nine neonatologic care units in southern Germany between Nov. 1, 1998 and Oct. 31, 1999. Questionnaires were sent to all parents of infants discharged from neonatal care units to determine the risk of rehospitalization for acute respiratory infections (ARI-RH) and RSV-RH in the 1999-2000 season. The questionnaire response rate was 68.4%. The 717 included infants of the responders had a mean gestational age of 31.6 weeks (Range: 23–35) and a mean birth weight of 1,747 g (range: 430–4,050 g). The risk for an ARI-RH was 10.6% and the risk for RSV-RH 5.2% during the observation period. Premature infants with chronic lung disease (CLD) had a probability of 24.5% for ARI-RH and of 15% for RSV-RH. The following factors were independently associated with an increased risk of RSV-RH: male gender (adjusted Odds-Ratio (OR): 8.7; 95% confidence interval (CI): 2.6–29.1), chronic lung disease (OR: 3.99; 95%CI: 1.4–11.2), discharge between October and December (OR: 2.1; 95%CI: 0.99–4.4), day-care attendance of siblings (OR: 3.9; 95%CI: 1.9–8.3). Conclusions: The risk for RSV rehospitalization among premature infants discharged from neonatal care facilities in southern Germany was low. Additional risk factors and high costs of prophylaxis have to be considered when infants are selected for RSV prophylaxis using monoclonal antibodies.

[1]  H. Moll,et al.  Treatment and prevention of respiratory syncytial virus infection , 2000, European Journal of Pediatrics.

[2]  P. Macmahon,et al.  Prophylaxis in RSV infection (Palivizumab)--is it worthwhile? , 2000, Irish medical journal.

[3]  M. Lebowitz,et al.  Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. , 1991, American journal of epidemiology.

[4]  S. Nachman,et al.  Rehospitalization with respiratory syncytial virus after neonatal intensive care unit discharge: A 3-year follow-up. , 1997, Pediatrics.

[5]  C. Xavier.  Guideline for the use of Synagis (Palivizumab), a humanized monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) disease in high risk infants a consensus opinion , 1999 .

[6]  J. Forster,et al.  Community and nosocomially acquired respiratory syncytial virus infection in a German paediatric hospital from 1988 to 1999 , 2001, European Journal of Pediatrics.

[7]  S. Poulsen,et al.  Epidemiology of respiratory syncytial virus infection requiring hospitalization in East Denmark. , 1998, The Pediatric infectious disease journal.

[8]  W. Maniscalco,et al.  Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. , 2000, Archives of pediatrics & adolescent medicine.

[9]  J. Eskola,et al.  EUROPEAN SOCIETY FOR PAEDIATRIC INFECTIOUS DISEASES , 1991, Pediatric Research.

[10]  M. Sharland,et al.  Hospitalisation for RSV infection in ex-preterm infants—implications for use of RSV immune globulin , 2000, Archives of disease in childhood.

[11]  J. Quero,et al.  Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons , 2001, The Pediatric infectious disease journal.

[12]  L. Wright,et al.  Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIV , 1998, Pediatrics.

[13]  J. Sinnott,et al.  Respiratory Syncytial Virus , 1988, Infection Control & Hospital Epidemiology.

[14]  W. Dankner.  Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants with Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin Prophylaxis , 1997, Pediatrics.

[15]  W. Puppe,et al.  Incidence of Respiratory Syncytial Virus-Positive Hospitalizations in Germany , 2001, European Journal of Clinical Microbiology and Infectious Diseases.

[16]  E. Wang,et al.  PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease. , 1997, Pediatrics.

[17]  M. Beresford,et al.  Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort , 2000, Archives of disease in childhood.

[18]  E. Grill,et al.  Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany , 2003, European Journal of Pediatrics.

[19]  C. Hall,et al.  Respiratory Syncytial Virus , 1983 .

[20]  D. J. Burch,et al.  International variation in the management of infants hospitalized with respiratory syncytial virus , 1998, European Journal of Pediatrics.

[21]  M. Sharland,et al.  Preventing respiratory syncitial virus bronchiolitis , 2001, BMJ : British Medical Journal.

[22]  A. Duppenthaler,et al.  Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infants. , 2001, Swiss medical weekly.

[23]  K. Gutierrez,et al.  Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. , 1988, Pediatrics.

[24]  G. Escobar,et al.  Rehospitalization for Respiratory Syncytial Virus Among Premature Infants , 1999, Pediatrics.

[25]  C. Hall,et al.  Development of local guidelines for prevention of respiratory syncytial viral infections. , 1999, The Pediatric infectious disease journal.